Steven Deeks, MD

Phone: 415-476-4082 ext. 330
UCSF Box: 0874
Email: [email protected]
UCSF Profile

Project Sponsor Location(s) Topics Start
 		End
Long Term Follow-Up of Patients Enrolled in Clinical Trials (#A-9602, A-9604, A-9801) Using Retroviral Gene Based Therapies / AIDS related research Cell Genesys, Inc. United States HIV/AIDS
Immediate Salvage Therapy w/ Combination ART plus T-20 vs. A 16 Week Structured Treatment Interruption Followed by Combination Therapy plus T-20 Trimeris, Inc. United States HIV/AIDS, Pharmacology and Drug Treatment
T Regulatory Cells and T Cell Activation in HIV Disease NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS, Immunology
Treatment Intensification for Drug-Resistant HIV NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS
Interruption of Enfuvirtide in Patients Experiencing an Incomplete Virologic Response to Enfuvirtide-Based Combination Antiretroviral Regimen Hoffman-LaRoche, Ltd. United States HIV/AIDS, Pharmacology and Drug Treatment
Enfuvirtide Intensification for Multi-Drug Resistant HIV California HIV/AIDS Research Program United States Zoonosis, Emerging Disease, and Drug Resistance, HIV/AIDS, Pharmacology and Drug Treatment
San Francisco National Clinical Trial Center, ESPIRIT University of Minnesota Morocco; Japan; Singapore; Thailand; Israel; Austria; Belgium; Denmark; France; Germany; Ireland; Italy; Netherlands; Norway; Poland; Portugal; Spain; United Kingdom; Argentina; Brazil; Canada; Australia HIV/AIDS, Pharmacology and Drug Treatment
Enfuvirtide Treatment Intensification in Patients with Multi-Drug Resistant HIV Hoffman-LaRoche, Ltd. United States HIV/AIDS, Pharmacology and Drug Treatment
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) University of Minnesota Tanzania; Zambia; Morocco; South Africa; Mali; Thailand; Greece; Argentina; Brazil; Chile; Peru HIV/AIDS
HIV Controllers: A Potential Model for HIV Eradication American Foundation for AIDS Research (AmFAR) United States HIV/AIDS, Immunology
HIV Entry Inhibitors: A New Therapeutic Option University of Pennsylvania United States HIV/AIDS, Immunology
International Network for Strategic Initiatives in Global HIV Trials/ ICR INSIGHT U.S. Department of Veterans Affairs South Africa; Mali; Brazil; Peru HIV/AIDS, Drug and Diagnostics Development
Master Agreement: International Network for Strategic Initiatives in Global HIV Trials/ICR INSIGHT U.S. Department of Veterans Affairs Uganda; South Africa; Mali; Nigeria; China; Malaysia; Thailand; Mexico; Argentina; Brazil; Chile; Peru; Uruguay HIV/AIDS
Preventing the Establishment of Enfuvirtide-Resistance in the Latent Reservoir NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS
Atripla Adherence and Resistance Relationships [I] Gilead Sciences, Inc. United States HIV/AIDS, Treatment Adherence
Elite Controllers Until There's a Cure Foundation United States HIV/AIDS, Immunology, Genetics
Atripla Adherence and Resistance Relationships [II] Bristol-Myers Squibb Company United States HIV/AIDS, Treatment Adherence
HIV Specific T-Cell Responses in Rectal Mucosa University of California Davis United States HIV/AIDS
Raltegravir Intensification in Antiretroviral-Treated Patients Exhibiting a Suboptimal CD4+T Cell Response Merck and Co., Inc. United States HIV/AIDS, Immunology
Core B: Specimen Repository Core Case Western Reserve University United States
Innate Effector Function and HIV-1 Control Wistar Institute United States HIV/AIDS, Immunology
UCSF/Ragon Collaboration on HIV "Elite" Controllers Massachusetts General Hospital United States HIV/AIDS, Drug and Diagnostics Development, Immunology, Genetics
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS, Pharmacology and Drug Treatment
EraMune Project Northwestern University United States
Epigenetic Regulation of HIV Latency J. David Gladstone Institutes United States HIV/AIDS
Treating HIV-infected Elite Controllers as a Model of HIV Remission Gilead Sciences, Inc. United States HIV/AIDS
The Impact of Early Antiretroviral Therapy on HIV Persistence and Inflammation NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS
Characterizing the Role of Immune Activation in HIV Persistence University of California Los Angeles (UCLA) United States HIV/AIDS, Immunology
Disulfiram to Accelerate Decay in HIV Reservoirs in ART Treated Patients Johns Hopkins University United States HIV/AIDS
DARE: Delaney AIDS Research Enterprise to Find a Cure NIH National Institute of Allergy and Infectious Disease Sweden; Australia HIV/AIDS
HIV Persistence after Successful CCR5-Depleted Stem Cell Transplantation American Foundation for AIDS Research (AmFAR) United States HIV/AIDS
AIDS Clinical Trials Network (ACTG)-Deeks (Co-Vice Chair) A5296 Brigham and Women's Hospital United States HIV/AIDS, Noncommunicable and/or Chronic Disease, Pharmacology and Drug Treatment
Impact of HIV-Associated Inflammation on Disease NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS
Master Agreement: R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS University of Alabama System United States HIV/AIDS
Task Order: R24 for the CFAR-Network for the Integrated Clinical Sciences, CNICS University of Alabama System United States
Short-Term Disulfiram Administration to Reverse Latent HIV Infection Monash University United States HIV/AIDS, Pharmacology and Drug Treatment
Identifying and Targeting HIV Persistence in T Cell Subsets during ART Vaccine and Gene Therapy Institute of Florida United States HIV/AIDS
Effects of CCR5 - delta-32 Heterozygosity on the HIV-1 Reservoir Vitalant Research Institute United States HIV/AIDS, Immunology, Genetics
Enhancing Control of HIV by Inhibiting TRAIL Mayo Foundation United States HIV/AIDS, Drug and Diagnostics Development, Immunology
Characterization of the HIV-1 Latent Reservoir in CCR5-Delta 32 Heterozygotes Vitalant Research Institute United States HIV/AIDS
Gender-specific Differences Affecting Reactivation of Latent HIV in Treated Patients Case Western Reserve University United States HIV/AIDS, Immunology, Women's Health
Impact of Sex-Based Differences on HIV Reservoir Size and Immune Activation Massachusetts General Hospital United States HIV/AIDS, Women's Health
Identifying and targeting HIV persistence in T Cell subsets during ART Vaccine and Gene Therapy Institute of Florida United States Drug and Diagnostics Development, Immunology, Genetics
Validation of Existing Ultra-Sensitive Assays for Quantifying HIV Persistence Vitalant Research Institute United States HIV/AIDS, Drug and Diagnostics Development
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): START University of Minnesota South Africa; Mali; Brazil; Peru HIV/AIDS, Drug and Diagnostics Development
Impact of interferon-alpha inhibition on immune function and viral persistence in HIV disease Bill & Melinda Gates Foundation United States HIV/AIDS, Immunology
Programming Long Term Durable HIV-1 Specific T cell Responses University of Pennsylvania United States HIV/AIDS, Immunology
Viral control mechanisms of HIV-specific T cells in HIV-infected lymph node University of Pennsylvania United States HIV/AIDS
Combination immune checkpoint blocker inhibition to eliminate HIV latency University of Melbourne, The United States HIV/AIDS, Drug and Diagnostics Development
Deeks Order CNICS: June 2014-Aug 2016 University of Alabama System United States HIV/AIDS
Delaney AIDS Research Enterprise to Cure HIV NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS, Drug and Diagnostics Development
Measuring the Latent reservoir for HIV Johns Hopkins University United States HIV/AIDS, Drug and Diagnostics Development
GS-US-382-3961: A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers Gilead Sciences, Inc. United States HIV/AIDS, Drug and Diagnostics Development
Therapeutic vaccination and PD-1 blockade in treated HIV disease NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS